Astellas Pharma Inc., of Tokyo, appointed Nate Crisel vice president, real world informatics and analytics; Gary Thal vice president, specialty, medical affairs, Americas; James Miteff national vice president, health systems payer and channel account management; and Gregory Apostol national vice president, key account management. Read More
Eutilex Co. Ltd., of Seoul, said it entered a strategic partnership with Zhejiang Huahai Pharmaceutical Ltd., of Shanghai, which will take a $30 million equity stake in Eutilex and in return receive an exclusive license to develop and commercialize EU-101, a humanized monoclonal antibody for cancer treatment, in the People's Republic of China, Taiwan, Hong Kong and Macau. Read More
PERTH, Australia – Companies in the regenerative medicine space have long been pushing the Therapeutic Goods Administration (TGA) to regulate autologous cell and tissue products in Australia, and they strongly support the agency's moves toward stronger regulation. Read More
The first 3-D map has been produced of the scaffold of a molecule called SgK223, which is now known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers. Read More
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) said the phase III trial of its oral vascular endothelial growth factor (VEGF) inhibitor fruquintinib has begun. Named FRUTIGA, the randomized, double-blind, placebo-controlled, multicenter study is to test fruquintinib's efficacy and safety in combination with chemotherapy paclitaxel for the treatment of advanced gastric cancer, or gastroesophageal junction adenocarcinoma, in China. Read More
PERTH, Australia – Novartis AG's recent tender offer to acquire radiopharmaceuticals specialist Advanced Accelerator Applications SA (AAA) for $3.9 billion could bode well for Aussie radiopharma company Telix Pharmaceuticals Ltd., which announced its IPO to raise A$50 million (US$38.4 million) on the Australian Securities Exchange. Read More
HONG KONG – In a pivotal phase III study, Tokyo-based Daiichi Sankyo Co. Ltd.'s pexidartinib met its primary endpoint of tumor response, measured by size reduction, in patients with symptomatic tenosynovial giant cell tumor (TGCT). Read More
